Braidwell LP Takes Position in Hemab Therapeutics Holdings, Inc. $COAG

Posted by Francis Steltz on Sep 3rd, 2026

Braidwell LP purchased a new stake in shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Free Report) during the second quarter, Holdings Channel reports. The institutional investor purchased 160,000 shares of the company’s stock, valued at approximately $5,877,000.

Insider Activity

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the transaction, the insider owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analyst Upgrades and Downgrades

Several research firms have issued reports on COAG. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. HC Wainwright lifted their price target on Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Jefferies Financial Group boosted their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. The Goldman Sachs Group began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Weiss Ratings started coverage on Hemab Therapeutics in a research note on Thursday, August 13th. They issued a “sell (d+)” rating for the company. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $51.40.

Read Our Latest Research Report on Hemab Therapeutics

Hemab Therapeutics Stock Up 1.5%

Hemab Therapeutics stock opened at $44.70 on Thursday. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $55.42. The company has a market cap of $2.09 billion and a price-to-earnings ratio of -1.80. The business’s 50 day moving average price is $44.66.

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.17). As a group, research analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.09 earnings per share for the current year.

Hemab Therapeutics Company Profile

(Free Report)

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.